• Free Daily Newsletter
  • Premium
  • Small Logo
  • About
  • Partner Pages
  • Support & FAQs
  • Log in

The Mandarin

The Mandarin
The Mandarin
  • Small Logo
  • Premium
  • Careers
    • Search SES Jobs
    • Career Advice
  • News
  • Editors' Picks
  • Portfolios
  • Events
  • Resource library
  • Small Logo
  • Premium
  • Careers
    • Search SES Jobs
    • Career Advice
  • News
  • Editors' Picks
  • Portfolios
  • Events
  • Resource library

Partner Content

Home Portfolio Health How can Australia usher in the new wave of immunotherapy cancer treatments?

How can Australia usher in the new wave of immunotherapy cancer treatments?

By Nerissa Bentley

Wednesday October 31, 2018

Doctors waiting outside hospital room

A new wave of immunotherapy cancer treatments are on our doorstep. And they have the potential to revolutionise the way we treat cancer.

These treatments use the body’s immune system to attack cancer cells, potentially offering greater survival prospects, without the side-effects of traditional cancer treatments, such as chemotherapy and radiation.

While these treatments – characterised by medicines that have multiple indications – are a breakthrough in treating cancer, providing widespread access remains a challenge for our current systems. Often, only those with significant financial means can afford them.

Treatment approval turnaround times need to improve

Immunotherapy cancer treatments in Australia are currently assessed based on where in the body the cancer originated. Because immunotherapies can have multiple indications, every indication requires a separate submission as if it were a new medicine, thereby slowing down the approval process, and creating budget uncertainty for the government.

At present, it takes an estimated 597 days for new cancer drugs to be approved after registration, which is on average, 200 days longer than other disease areas.

The European perspective

However, our European counterparts have overcome similar challenges, by introducing Multi-Year Multi-Indication (MYMI) agreements. This innovative approach has resulted in:

  • significant reductions in reimbursement approval times,
  • reduced workload and time required for indication assessments,
  • budget predictability for both payers and manufacturers,
  • increased incentives to launch all indications as quickly as possible.

With cancer being one of the leading causes of morbidity and mortality in Australia, it’s imperative that we devise solutions that allow immunotherapies to reach Australians with cancer as quickly as possible, whilst maintaining budget predictability.

About the author

By Nerissa Bentley

Nerissa Bentley is “The Melbourne Health Writer”; a health communications specialist who works with small businesses, institutions and national brands, to create credible, easy-to-understand health content. Nerissa has written for a large number of national organisations including Fitness Australia, Chemmart, Bupa and Defence Health. She also writes health copy for smaller health-based businesses including dental and medical practices, allied health professionals, personal trainers, and counsellors.

People: Dr Deme Karikios Megan Bohensky Sharon Winton

Companies: Merck Merck Research Laboratories

Departments: Department of Health Department of Health and Human Services

Partners: MSD

Tags: cancer cancer treatment Immuno-Oncology immunotherapy

Login
Please login to comment
0 Comments
Inline Feedbacks
View all comments

The essential resource for effective
public sector professionals

Check out the Latest

By Nerissa Bentley

Wednesday October 31, 2018
Text size: A A A

Upcoming Events

11
Feb
Reverse and Reciprocal Mentoring Webinar
15
Feb
Applying Behavioural Science to Create Change
16
Feb
Innovation Reset 2020: Trust | Empathy | Competence – How the new public work is the new work of government, the public service and many others too.
17
Feb
Proud Partnerships in Place: 2021 First Peoples Public Administration Virtual Conference
10
Feb
BSB41015 Certificate IV in Human Resources
View Calendar

Partner Content

Whitepaper: Leveraging government data in a multi-cloud world

Whitepaper: Leveraging government data in a multi-cloud world

A national platform university?
Promoted

A national platform university?

Why cloud-based backup is critical for public sector agencies in the post-COVID world
Promoted

Why cloud-based backup is critical for public sector agencies in the post-COVID world

Latest Jobs


  • Deputy Under Treasurer

    Department of Treasury and Finance

    • NT CBD
    Closing date 18th February, 2021
    4 days ago Full Time - Fixed Term
  • Chief People & Culture Officer

    TAFE NSW

    • NSW
    Closing date 12th February, 2021
    8 days ago Full Time - Ongoing
  • Director, Media (Multiple Roles)

    NSW Ministry of Health

    • NSW
    Closing date 15th February, 2021
    8 days ago Full Time - Fixed Term
  • Assistant Secretary

    Department of the Treasury

    • ACT
    Closing date 21st February, 2021
    13 days ago Full Time - Fixed Term
  • Group Manager Participation and Family Payments

    Department of Social Services

    • ACT CBD
    Closing date 18th February, 2021
    6 days ago
  • ACT Integrity Commissioner

    ACT Legislative Assembly

    • ACT CBD
    Closing date 19th February, 2021
    14 days ago Part Time - Fixed Term
Search All Jobs

Login

New to The Mandarin? Create an account

Forgot password?

Share via email

Access your 3 free Mandarin Premium articles

As part of your free trial you will receive 'The Juice', The Mandarin's daily free newsletter, the 'Premium wrap' every Saturday and marketing emails. You can opt out at any time.
Content
  • Small Logo
  • News
  • Research Series
  • Features
  • Portfolios
  • Jurisdictions
  • New Zealand
  • People & Capability
  • Thought Leadership
  • Editors' Picks
  • Resource Library
  • Site Map
Products & Services
  • Small Logo
  • The Juice Newsletter
  • Partner & Advertising solutions
  • Mandarin Live
  • Public Sector Events Calendar
  • Partner Content
  • Premium
  • Careers
Legal
  • Small Logo
  • Privacy Policy
  • Terms of Usage
  • Code of Conduct
Connect
  • Small Logo
  • About Us
  • Contact Us
  • Support
  • Our Team
Social
Copyright © The Mandarin
Private Media logo CRIKEY SMARTCOMPANY STARTUPSMART
wpDiscuz